1
|
Madumarov AS, Aksenov NV, Bozhikov GA, Astakhov AA, Albin YV, Bulavin MV, Shabalin EP, Dmitriev SN. Study of activation cross sections of double neutron capture reaction on 193Ir for the reactor production route of radiotherapeutic 195mPt. Nucl Med Biol 2024; 134-135:108928. [PMID: 38776715 DOI: 10.1016/j.nucmedbio.2024.108928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2023] [Revised: 05/08/2024] [Accepted: 05/17/2024] [Indexed: 05/25/2024]
Abstract
The radiotherapeutic 195mPt is among the most effective Auger electron emitters of the currently studied radionuclides that have a potential theranostic application in nuclear medicine. Production of 195mPt through double neuron capture of enriched 193Ir followed by β--decay to the radioisotope of interest carried out at the research reactor IBR-2 is described. Because of the high radiation background, radiochemical purification procedure of 195mPt from bulk of iridium was needed to be developed and is detailed here as well. For the first time, cross section and resonance integral for the reaction 194Ir(n,γ)195mIr were determined. Resonance neutrons contribution was established to exceed that of thermal neutrons, and resonance integral for the reaction 194Ir(n,γ)195mIr is calculated to be 2900 b. Specific activity of 195mPt was estimated to reach a value of 38.7 GBq/(g Pt) at IBR-2 by the end of bombardment (EOB).
Collapse
Affiliation(s)
- Alexander S Madumarov
- Flerov Laboratory of Nuclear Reactions, Joint Institute for Nuclear Research, Joliot-Curie 6, 141980 Dubna, Russia.
| | - Nikolay V Aksenov
- Flerov Laboratory of Nuclear Reactions, Joint Institute for Nuclear Research, Joliot-Curie 6, 141980 Dubna, Russia.
| | - Gospodin A Bozhikov
- Flerov Laboratory of Nuclear Reactions, Joint Institute for Nuclear Research, Joliot-Curie 6, 141980 Dubna, Russia.
| | - Andrey A Astakhov
- Flerov Laboratory of Nuclear Reactions, Joint Institute for Nuclear Research, Joliot-Curie 6, 141980 Dubna, Russia.
| | - Yury V Albin
- Flerov Laboratory of Nuclear Reactions, Joint Institute for Nuclear Research, Joliot-Curie 6, 141980 Dubna, Russia.
| | - Maksim V Bulavin
- Frank Laboratory of Neutron Physics, Joint Institute for Nuclear Research, Joliot-Curie 6, 141980 Dubna, Russia
| | - Evgeny P Shabalin
- Frank Laboratory of Neutron Physics, Joint Institute for Nuclear Research, Joliot-Curie 6, 141980 Dubna, Russia.
| | - Sergey N Dmitriev
- Flerov Laboratory of Nuclear Reactions, Joint Institute for Nuclear Research, Joliot-Curie 6, 141980 Dubna, Russia.
| |
Collapse
|
2
|
Owolabi P, Adam Y, Adebiyi E. Personalizing medicine in Africa: current state, progress and challenges. Front Genet 2023; 14:1233338. [PMID: 37795248 PMCID: PMC10546210 DOI: 10.3389/fgene.2023.1233338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Accepted: 09/11/2023] [Indexed: 10/06/2023] Open
Abstract
Personalized medicine has been identified as a powerful tool for addressing the myriad of health issues facing different health systems globally. Although recent studies have expanded our understanding of how different factors such as genetics and the environment play significant roles in affecting the health of individuals, there are still several other issues affecting their translation into personalizing health interventions globally. Since African populations have demonstrated huge genetic diversity, there is a significant need to apply the concepts of personalized medicine to overcome various African-specific health challenges. Thus, we review the current state, progress, and challenges facing the adoption of personalized medicine in Africa with a view to providing insights to critical stakeholders on the right approach to deploy.
Collapse
Affiliation(s)
- Paul Owolabi
- Covenant Applied Informatics and Communication, Africa Centre of Excellence (CApIC-ACE), Covenant University, Ota, Ogun State, Nigeria
- Department of Computer and Information Science, Covenant University, Ota, Ogun State, Nigeria
| | - Yagoub Adam
- Covenant University Bioinformatics Research (CUBRe), Covenant University, Ota, Ogun State, Nigeria
| | - Ezekiel Adebiyi
- Covenant Applied Informatics and Communication, Africa Centre of Excellence (CApIC-ACE), Covenant University, Ota, Ogun State, Nigeria
- Department of Computer and Information Science, Covenant University, Ota, Ogun State, Nigeria
- Covenant University Bioinformatics Research (CUBRe), Covenant University, Ota, Ogun State, Nigeria
- Applied Bioinformatics Division, German Cancer Research Center (DKFZ), Heidelberg, Germany
| |
Collapse
|
3
|
Wawrowicz K, Żelechowska-Matysiak K, Majkowska-Pilip A, Wierzbicki M, Bilewicz A. Platinum nanoparticles labelled with iodine-125 for combined "chemo-Auger electron" therapy of hepatocellular carcinoma. NANOSCALE ADVANCES 2023; 5:3293-3303. [PMID: 37325536 PMCID: PMC10262957 DOI: 10.1039/d3na00165b] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 05/12/2023] [Indexed: 06/17/2023]
Abstract
Convenient therapeutic protocols against hepatocellular carcinoma (HCC) exhibit low treatment effectiveness, especially in the context of long-term effects, which is primarily related to late diagnosis and high tumor heterogeneity. Current trends in medicine concern combined therapy to achieve new powerful tools against the most aggressive diseases. When designing modern, multimodal therapeutics, it is necessary to look for alternative routes of specific drug delivery to the cell, its selective (with respect to the tumor) activity and multidirectional action, enhancing the therapeutic effect. Targeting the physiology of the tumor makes it possible to take advantage of certain characteristic properties of the tumor that differentiate it from other cells. In the present paper we designed for the first time iodine-125 labeled platinum nanoparticles for combined "chemo-Auger electron" therapy of hepatocellular carcinoma. High selectivity achieved by targeting the tumor microenvironment of these cells was associated with effective radionuclide desorption in the presence of H2O2. The therapeutic effect was found to be correlated with cell damage at various molecular levels including DNA DSBs and was observed in a dose-dependent manner. A three-dimensional tumor spheroid revealed successful radioconjugate anticancer activity with a significant treatment response. A possible concept for clinical application after prior in vivo trials may be achieved via transarterial injection of micrometer range lipiodol emulsions with encapsulated 125I-NP. Ethiodized oil gives several advantages especially for HCC treatment; thus bearing in mind a suitable particle size for embolization, the obtained results highlight the exciting prospects for the development of PtNP-based combined therapy.
Collapse
Affiliation(s)
- Kamil Wawrowicz
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology Dorodna 16 St. 03-195 Warsaw Poland
| | - Kinga Żelechowska-Matysiak
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology Dorodna 16 St. 03-195 Warsaw Poland
| | - Agnieszka Majkowska-Pilip
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology Dorodna 16 St. 03-195 Warsaw Poland
- Department of Nuclear Medicine, Central Clinical Hospital of the Ministry of the Interior and Administration Wołoska 137 St. 02-507 Warsaw Poland
| | - Mateusz Wierzbicki
- Department of Nanobiotechnology, Institute of Biology, Warsaw University of Life Sciences Ciszewskiego 8 St. 02-786 Warsaw Poland
| | - Aleksander Bilewicz
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology Dorodna 16 St. 03-195 Warsaw Poland
| |
Collapse
|
4
|
|
5
|
Abstract
Nuclear medicine is composed of two complementary areas, imaging and therapy. Positron emission tomography (PET) and single-photon imaging, including single-photon emission computed tomography (SPECT), comprise the imaging component of nuclear medicine. These areas are distinct in that they exploit different nuclear decay processes and also different imaging technologies. In PET, images are created from the 511 keV photons produced when the positron emitted by a radionuclide encounters an electron and is annihilated. In contrast, in single-photon imaging, images are created from the γ rays (and occasionally X-rays) directly emitted by the nucleus. Therapeutic nuclear medicine uses particulate radiation such as Auger or conversion electrons or β- or α particles. All three of these technologies are linked by the requirement that the radionuclide must be attached to a suitable vector that can deliver it to its target. It is imperative that the radionuclide remain attached to the vector before it is delivered to its target as well as after it reaches its target or else the resulting image (or therapeutic outcome) will not reflect the biological process of interest. Radiochemistry is at the core of this process, and radiometals offer radiopharmaceutical chemists a tremendous range of options with which to accomplish these goals. They also offer a wide range of options in terms of radionuclide half-lives and emission properties, providing the ability to carefully match the decay properties with the desired outcome. This Review provides an overview of some of the ways this can be accomplished as well as several historical examples of some of the limitations of earlier metalloradiopharmaceuticals and the ways that new technologies, primarily related to radionuclide production, have provided solutions to these problems.
Collapse
Affiliation(s)
- Eszter Boros
- Department of Chemistry , Stony Brook University , Stony Brook , New York 11794 , United States
| | - Alan B Packard
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology , Boston Children's Hospital , Boston , Massachusetts 02115 , United States.,Harvard Medical School , Boston , Massachusetts 02115 , United States
| |
Collapse
|
6
|
Excitation functions of proton- and deuteron-induced nuclear reactions on natural iridium for the production of 191Pt. Appl Radiat Isot 2018; 137:250-260. [PMID: 29679927 DOI: 10.1016/j.apradiso.2018.03.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2018] [Revised: 03/21/2018] [Accepted: 03/27/2018] [Indexed: 11/20/2022]
Abstract
We studied the excitation functions of residual radionuclides produced via proton and deuteron bombardment on natural iridium in the energy ranges of 30-15 MeV and 50-15 MeV, respectively. A conventional stacked-foil activation technique combined with HPGe γ-ray spectrometry was used to measure the excitation functions for 189, 191Pt and 189, 190g, 192g, 194gIr radionuclide production. Theoretical thick target yields were estimated to be 172 MBq/µA h and 192 MBq/µA h via the 193Ir(p,3n)191Pt reaction at 29.6-17.5 MeV and the 193Ir(d,4n)191Pt reaction at 40.3-23.8 MeV, respectively. The feasibility of 191Pt production from an iridium target was discussed, and compared with previously reported methods for the production of 191Pt.
Collapse
|
7
|
Cheff DM, Hall MD. A Drug of Such Damned Nature.1 Challenges and Opportunities in Translational Platinum Drug Research. J Med Chem 2017; 60:4517-4532. [DOI: 10.1021/acs.jmedchem.6b01351] [Citation(s) in RCA: 64] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Affiliation(s)
- Dorian M. Cheff
- NCATS Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| | - Matthew D. Hall
- NCATS Chemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, 9800 Medical Center Drive, Rockville, Maryland 20850, United States
| |
Collapse
|
8
|
Severin GW, Nielsen CH, Jensen AI, Fonslet J, Kjær A, Zhuravlev F. Bringing Radiotracing to Titanium-Based Antineoplastics: Solid Phase Radiosynthesis, PET and ex Vivo Evaluation of Antitumor Agent [45Ti](salan)Ti(dipic). J Med Chem 2015; 58:7591-5. [DOI: 10.1021/acs.jmedchem.5b01167] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Affiliation(s)
- Gregory W. Severin
- Hevesy
Laboratory, Center for Nuclear Technologies at the Technical University of Denmark, Frederiksborgvej 399, 4000 Roskilde, Denmark
| | - Carsten H. Nielsen
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark
- Minerva Imaging, Ole Maaløes
Vej 3, 2200 Copenhagen, Denmark
| | - Andreas I. Jensen
- Hevesy
Laboratory, Center for Nuclear Technologies at the Technical University of Denmark, Frederiksborgvej 399, 4000 Roskilde, Denmark
| | - Jesper Fonslet
- Hevesy
Laboratory, Center for Nuclear Technologies at the Technical University of Denmark, Frederiksborgvej 399, 4000 Roskilde, Denmark
| | - Andreas Kjær
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen, Denmark
| | - Fedor Zhuravlev
- Hevesy
Laboratory, Center for Nuclear Technologies at the Technical University of Denmark, Frederiksborgvej 399, 4000 Roskilde, Denmark
| |
Collapse
|
9
|
Biodistribution of a potential chemotherapeutic, dinuclearbisphosphinogold(I) dithiocarbamate, as determined by its 198Au radiolabelled analogue. J Radioanal Nucl Chem 2014. [DOI: 10.1007/s10967-014-3816-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|